Ennov, the provider of the only unified compliance platform for Life Sciences – a highly configurable software architecture that provides a consistent user experience and eliminates data silos –, has today announced the acquisition of MACRO, a world-class and trusted trial resource provider of advanced EDC (Electronic Data Capture) software for clinical research from Elsevier.
MACRO’s easy-to-use system allows users to quickly input, monitor and run reports on subject data to collect accurate and reliable data for analysis. With its powerful capabilities to meet internationally recognized ethical and scientific quality requirements for the design, conduct, registration and reporting of clinical trials involving human subjects, MACRO has become the benchmark solution for clinical research institutions in the UK. MACRO also serves world-class research institutions in Austria, Germany, Ireland, Spain, Sweden and Switzerland.
This acquisition makes Ennov the leading provider in clinical trial and compliance solutions in the European region. More specifically, MACRO’s customers include many cancer research institutes in the UK as well as in France, underlining Ennov’s leading position. In total, more than 20 cancer research institutions worldwide will conduct their studies on one of Ennov’s solutions. 9 out of these 20 institutions were ranked among the top 100 cancer hospitals in the world by Newsweek magazine’s World’s Best Hospitals 2021.
“This acquisition reflects Ennov and MACRO’s shared vision of providing customers with the most comprehensive and cost-effective suite of software solutions for efficiently running compliant clinical trials. We are thrilled to welcome our new team and to share our skills and expertise.”
Olivier Pâris, Chairman of Ennov
“We are delighted the MACRO team will be joining Ennov, which has an excellent reputation in the industry. MACRO is a great fit for Ennov’s end-to-end solution and customers will benefit from the combined offering, world-class expertise and continuity of service.”
Olaf Lodbrok, Senior Vice President of Precision Medicine at Elsevier
Media contact at Ennov:
Laure BROS
[email protected]
About Ennov
Ennov is a French-based software company specializing in Life Sciences. Ennov develops unified software solutions that integrate with its clients’ existing workflow for true productivity gains. The Ennov holistic approach allows for a uniform information system with an unmatched price-performance ratio. Seamless integration between all platform facets provides a cohesive information system and divides the overall cost of the IT chain by 10. Ennov goes beyond the limitations of traditional solution providers and focus on creating easy-to-use, elegant software, resulting in high user acceptance and one of the highest customer satisfaction rates in the industry (96% renewal rate).
About Elsevier
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.
Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress.
Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including “The Lancet” and ”Cell”; our 40,000 e-Book titles; and our iconic reference works, such as “Gray’s Anatomy.” With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
